Julie Gralow: New ASCO recommendations on the need for collection of ovarian toxicity in cancer clinical trials!

Julie Gralow, shared a post by ASCO on X/Twitter, adding:

“New ASCO recommendations on the need for collection of ovarian toxicity in cancer clinical trials!”

Quoting ASCO’s post:

“Our new recommendations published today in our new recommendations published today in The Lancet Oncology spotlight the need for assessing ovarian toxicity in clinical trials. This aims to bridge the information gap helping patients make informed treatment choices.”

For details click here.
For the video click here.
Sources: Julie Gralow/Twitter and ASCO/Twitter

Julie Gralow is the Chief Medical Officer (CMO) and Executive Vice President of the American Society of Clinical Oncology (ASCO). Previously, she was the Jill Bennett Endowed Professor of Breast Cancer at the University of Washington School of Medicine, Professor in the Clinical Research Division of the Fred Hutchinson Cancer Research Center, as well as Director of Breast Medical Oncology at the Seattle Cancer Care Alliance. She is the founder of the Women’s Empowerment Cancer Advocacy Network (WE CAN). Dr. Gralow received the ASCO Humanitarian Award in 2018 for her work in empowering women cancer patients and survivors globally.